文献速递银屑病与炎症性皮肤病皮肤肿瘤

白癜风患者长期窄谱UVB光疗与皮肤癌及癌前病变风险

Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy.
PubMed 文献 · JAMA Dermatol · 2020-01-01

这项韩国全国性回顾性队列研究纳入60 321例20岁以上白癜风患者,按NBUVB光疗次数分组。结果显示,Bowen病、非黑色素瘤皮肤癌和黑色素瘤风险未随光疗次数增加而升高;但≥200次光疗者光化性角化病风险显著增加(HR 2.269,95%CI 1.530-3.365)。

要点

  • 长期NBUVB光疗未增加白癜风患者皮肤癌风险
  • ≥200次光疗时光化性角化病风险显著升高
  • ≥500次光疗者非黑色素瘤皮肤癌和黑色素瘤风险未增加

核心结论

  • 长期NBUVB光疗与白癜风患者皮肤癌风险增加无关,可视为安全治疗。

研究设计与样本

  • 全国性基于人群的回顾性队列研究,纳入2007年1月1日至2017年12月31日韩国国民健康保险索赔数据库60 321例20岁以上白癜风患者。
  • 按2008至2017年光疗次数分为5组:0次(20 105例)、1-49次(20 106例)、50-99次(9702例)、100-199次(6226例)、≥200次(4182例),并识别≥500次者(717例)。

主要发现

  • Bowen病风险未增加:<50次HR 0.289(95%CI 0.060-1.392),50-99次HR 0.603(95%CI 0.125-2.904),100-199次HR 1.273(95%CI 0.329-4.924),≥200次HR 1.021(95%CI 0.212-4.919)。
  • 非黑色素瘤皮肤癌风险未增加:<50次HR 0.914(95%CI 0.533-1.567),50-99次HR 0.765(95%CI 0.372-1.576),100-199次HR 0.960(95%CI 0.453-2.034),≥200次HR 0.905(95%CI 0.395-2.073)。
  • 黑色素瘤风险未增加:<50次HR 0.660(95%CI 0.286-1.526),50-99次HR 0.907(95%CI 0.348-2.362),100-199次HR 0.648(95%CI 0.186-2.255),≥200次HR 0.539(95%CI 0.122-2.374)。
  • 光化性角化病风险在≥200次光疗者中显著增加(HR 2.269,95%CI 1.530-3.365)。
  • ≥500次光疗者非黑色素瘤皮肤癌风险未高于未光疗者(HR 0.563,95%CI 0.076-4.142),黑色素瘤HR不适用。

关键数值与推荐

  • 光化性角化病风险在≥200次NBUVB光疗者中显著增加,HR 2.269(95%CI 1.530-3.365)。
  • Bowen病、非黑色素瘤皮肤癌和黑色素瘤风险在各光疗次数组均未显著增加。

临床怎么用

  • 长期NBUVB光疗治疗白癜风时,皮肤癌风险未见增加,可考虑为安全治疗选择。
  • 对接受≥200次光疗者应关注光化性角化病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Narrowband UV-B (NBUVB) phototherapy has been the mainstay in the treatment of vitiligo, but its long-term safety in terms of photocarcinogenesis has not been established. OBJECTIVES: To investigate the risks of skin cancer and precancerous lesions among patients with vitiligo undergoing NBUVB phototherapy, based on the number of NBUVB phototherapy sessions. DESIGN, SETTING, AND PARTICIPANTS: This nationwide population-based retrospective cohort study enrolled 60 321 patients with vitiligo 20 years or older between January 1, 2007, and December 31, 2017. Patients and outcomes were identified through nationwide cohort data from the Korean national health insurance claims database, and frequency matching by age and sex was performed. EXPOSURES: The number of phototherapy sessions each patient received between 2008 and 2017. Patients were classified into 5 groups according to the number of phototherapy sessions (0 sessions, 20 105 patients; 1-49 sessions, 20 106 patients; 50-99 sessions, 9702 patients; 100-199 sessions, 6226 patients; and ≥200 sessions, 4182 patients). We also identifed patients who underwent at least 500 phototherapy sessions (717 patients). MAIN OUTCOMES AND MEASURES: Primary outcomes were the development of actinic keratosis, Bowen disease, nonmelanoma skin cancer, or melanoma after enrollment. RESULTS: Among the 60 321 patients with vitiligo in this study (33 617 women; mean [SD] age, 50.2 [14.9] years), the risks of Bowen disease (<50 sessions of phototherapy: hazard ratio [HR], 0.289 [95% CI, 0.060-1.392]; 50-99 sessions: HR, 0.603 [95% CI, 0.125-2.904]; 100-199 sessions: HR, 1.273 [95% CI, 0.329-4.924]; ≥200 sessions: HR, 1.021 [95% CI, 0.212-4.919]), nonmelanoma skin cancer (<50 sessions: HR, 0.914 [95% CI, 0.533-1.567]; 50-99 sessions: HR, 0.765 [95% CI, 0.372-1.576]; 100-199 sessions: HR, 0.960 [95% CI, 0.453-2.034]; ≥200 sessions: HR, 0.905 [95% CI, 0.395-2.073]), and melanoma (<50 sessions: HR, 0.660 [95% CI, 0.286-1.526]; 50-99 sessions: HR, 0.907 [95% CI, 0.348-2.362]; 100-199 sessions: HR, 0.648 [95% CI, 0.186-2.255]; ≥200 sessions: HR, 0.539 [95% CI, 0.122-2.374]) did not increase after phototherapy. The risk of actinic keratosis increased significantly for those who had undergone 200 or more NBUVB phototherapy sessions (HR, 2.269 [95% CI, 1.530-3.365]). A total of 717 patients with vitiligo underwent at least 500 sessions of NBUVB phototherapy; their risks of nonmelanoma skin cancer and melanoma were no greater than those of the patients who did not undergo NBUVB phototherapy (nonmelanoma skin cancer: HR, 0.563 [95% CI, 0.076-4.142]; melanoma: HR, not applicable). CONCLUSIONS AND RELEVANCE: Our results suggest that long-term NBUVB phototherapy is not associated with an increased risk of skin cancer in patients with vitiligo and that NBUVB phototherapy may be considered a safe treatment.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Bae JM, Ju HJ, Lee RW, et al. Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy. JAMA Dermatol. 2020. PMID: 32159729. doi:10.1001/jamadermatol.2020.0218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。